MCID: PNC008
MIFTS: 39

Pancreatic Endocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 15 17 71
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 44
Islet Cell Carcinoma 12
Carcinoma Islet Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD9CM 34 157.4
MeSH 44 D018273
NCIt 50 C3770
SNOMED-CT 67 254612002
ICD10 32 C25.4
UMLS 71 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to glucagonoma and zollinger-ellison syndrome. An important gene associated with Pancreatic Endocrine Carcinoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Signaling by GPCR and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Sunitinib and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and pancreatic islet, and related phenotype is behavior/neurological.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
# Related Disease Score Top Affiliating Genes
1 glucagonoma 30.4 SST GAST CHGA
2 zollinger-ellison syndrome 30.4 SST MEN1 GAST CHGA
3 peptic ulcer disease 30.2 SST MEN1 GAST
4 duodenal ulcer 30.1 SST INS GAST
5 lung large cell carcinoma 30.0 SYP NCAM1 CHGA
6 hyperparathyroidism 29.9 PTHLH MEN1 GAST CHGA
7 cholelithiasis 29.9 SST INS GAST
8 multiple endocrine neoplasia 29.9 SST MEN1 GAST CHGA
9 carcinoid syndrome 29.8 SYP SST MEN1 CHGA
10 somatostatinoma 29.8 SSTR2 SST PPY MEN1 INS GCG
11 von hippel-lindau syndrome 29.8 SYP SST MEN1 CHGA
12 merkel cell carcinoma 29.7 SYP SST NCAM1 CHGA
13 acinar cell carcinoma 29.7 SERPINA3 GAST CHGA AFP
14 large cell carcinoma 29.7 SYP PTHLH NCAM1 CHGA
15 hyperinsulinism 29.6 SST INS GCG
16 tuberous sclerosis 29.5 SYP SST INS CHGA
17 type 1 diabetes mellitus 29.4 SST MEG3 INS GCG
18 acromegaly 29.4 SSTR5 SSTR2 SST MEN1 INS
19 primary hyperparathyroidism 29.4 PTHLH MEN1 INS GAST CHGA
20 pheochromocytoma 29.3 SYP SST NCAM1 MEN1 MEG3 CHGA
21 neuroendocrine tumor 29.3 SYP SSTR2 SST NCAM1 MEN1 GAST
22 islet cell tumor 29.2 SYP SST SERPINA3 PTHLH PPY MEN1
23 neuroendocrine carcinoma 29.1 SYP SST NCAM1 GCG GAST CHGA
24 gastrinoma 28.9 SSTR5 SSTR2 SST MEN1 INS GAST
25 insulinoma 28.8 SSTR5 SSTR2 SST MEN1 INS GCG
26 pancreatic cholera 28.4 SST PPY MEN1 GCG GAST CHGA
27 diabetes mellitus 28.1 SST MEN1 MEG3 INS GCG GAST
28 multiple endocrine neoplasia, type i 28.0 SYP SST PPY MEN1 INS GCG
29 pancreatic cancer 28.0 SSTR2 SST SERPINA3 PTHLH MEN1 MEG3
30 neuroendocrine carcinoma of pancreas 11.2
31 lung combined type small cell carcinoma 10.4 SYP NCAM1
32 hypoganglionosis 10.4 SYP NCAM1
33 glomangiosarcoma 10.4 SYP NCAM1
34 cerebellopontine angle primitive neuroectodermal tumor 10.4 SYP NCAM1
35 orbital cancer 10.3 SYP NCAM1
36 prostate stromal sarcoma 10.3 SYP NCAM1
37 extraosseous ewing sarcoma 10.3 SYP NCAM1
38 thymus sarcomatoid carcinoma 10.3 SYP AFP
39 pineal region teratoma 10.3 SYP AFP
40 nasal cavity olfactory neuroblastoma 10.3 SYP NCAM1
41 functionless pituitary adenoma 10.3 SST MEG3
42 tsh producing pituitary tumor 10.3 SSTR5 SST
43 oncogenic osteomalacia 10.3 SSTR5 PTHLH
44 adult type testicular granulosa cell tumor 10.3 NCAM1 AFP
45 hypokalemia 10.3
46 non-gestational ovarian choriocarcinoma 10.3 NCAM1 AFP
47 ovarian germ cell teratoma 10.3 SYP AFP
48 infected hydrocele 10.3 NCAM1 AFP
49 gastric antral vascular ectasia 10.3 SST GAST
50 papillary ependymoma 10.3 SYP MEN1

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

MGI Mouse Phenotypes related to Pancreatic Endocrine Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.32 AFP INS NCAM1 PPY PTHLH SERPINA3

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 3 341031-54-7, 557795-19-4 5329102
2 Angiogenesis Inhibitors Phase 3
3
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
4
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
5
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
6
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
7
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
8
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
9
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
10
Etoposide Approved Phase 2 33419-42-0 36462
11
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
12
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
13
nivolumab Approved Phase 2 946414-94-4
14
Ipilimumab Approved Phase 2 477202-00-9
15
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
16
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
17
Bevacizumab Approved, Investigational Phase 2 216974-75-3
18
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
19
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
20
Pancrelipase Approved, Investigational Phase 2 53608-75-6
21
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
22
leucovorin Approved Phase 2 58-05-9 6006
23
Fluorouracil Approved Phase 2 51-21-8 3385
24
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
25
Lenograstim Approved, Investigational Phase 2 135968-09-1
26
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
27
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29 Molgramostim Investigational Phase 2 99283-10-0
30 Antifungal Agents Phase 2
31 Anti-Infective Agents Phase 2
32 Immunoglobulin G Phase 2
33 Endothelial Growth Factors Phase 2
34 Insulin, Globin Zinc Phase 2
35 insulin Phase 2
36 Etoposide phosphate Phase 2
37 Nutrients Phase 2
38 Protective Agents Phase 2
39 Micronutrients Phase 2
40 Vitamin B Complex Phase 2
41 Trace Elements Phase 2
42 Vitamins Phase 2
43 Vitamin B9 Phase 2
44 Folate Phase 2
45 topoisomerase I inhibitors Phase 2
46 Antidotes Phase 2
47 Antimetabolites Phase 2
48 Alkylating Agents Phase 1, Phase 2
49 Antineoplastic Agents, Immunological Phase 2
50 Immunoglobulins Phase 2

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
2 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
3 An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
4 A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
5 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
6 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
7 Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
8 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
9 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
10 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
11 Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT02101918 Phase 2
12 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
13 A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma Completed NCT00781911 Phase 2 depot octreotide
14 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II. Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
15 Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
16 Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin Recruiting NCT03736720 Phase 2 Fluorouracil;Leucovorin;Liposomal Irinotecan
17 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
18 A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET) Active, not recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
19 A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
20 A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 Capecitabine;Temozolomide
21 A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) Active, not recruiting NCT02893930 Phase 2 Sapanisertib
22 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
23 A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Terminated NCT02031536 Phase 2 everolimus
24 Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma Terminated NCT02273752 Phase 2 Everolimus
25 Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Terminated NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
26 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
27 Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy Withdrawn NCT02108782 Phase 2 dovitinib lactate
28 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
29 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
30 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
31 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
32 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
33 An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment Completed NCT00428220 sunitinib
34 A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Completed NCT01603004
35 "CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial" Recruiting NCT01365169
36 "What Do You Value?" A Survey Study Assessing How Patients and Health Care Providers Weigh the Different Components of the Value Equation Recruiting NCT04483349
37 Diagnosis of Pancreatic Cystic Lesions With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy Active, not recruiting NCT03884179
38 Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization Terminated NCT00730483 PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Dacarbazine

Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

40
Pancreas, Liver, Pancreatic Islet, Endothelial, Breast, Cervix

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show top 50) (show all 154)
# Title Authors PMID Year
1
Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite Shift. 61
32388775 2020
2
Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation. 61
33288156 2020
3
A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms. 61
33181635 2020
4
Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. 61
32891532 2020
5
[The Efficacy of 17 Cases of Pancreaticoduodenectomy Combined with Vascular Resection and Reconstruction by Using Robotic Operation System (with Video)]. 61
32691551 2020
6
Nonfunctional Pancreatic Neuroendocrine Carcinoma With Isolated Retroperitoneal Metastasis: A Case Report and Literature Review. 61
32101939 2020
7
Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules. 61
32293342 2020
8
Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma. 61
32138704 2020
9
RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis. 61
32001819 2020
10
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. 61
33101770 2020
11
The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas. 61
31357196 2020
12
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial). 61
31986515 2020
13
[A Case of Pancreatic Neuroendocrine Carcinoma Presenting Multiple Liver Metastasis as an Initial Manifestation for Which Diagnosis Confirmation Was Difficult]. 61
32156886 2019
14
A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification. 61
31509453 2019
15
LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. 61
32010361 2019
16
Hepatobiliary and Pancreatic: A procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma. 61
30663800 2019
17
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. 61
30863939 2019
18
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. 61
30898132 2019
19
Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. 61
30182253 2019
20
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. 61
29912000 2019
21
Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. 61
31236541 2019
22
[A Case of Successful Treatment of Recurrent Liver Metastases from Mixed Adenoneuroendocrine Carcinoma of the Pancreas with Everolimus Administration]. 61
30587736 2018
23
The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. 61
30308534 2018
24
TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas. 61
30030118 2018
25
The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. 61
30333055 2018
26
Cutaneous metastases of pancreatic neuroendocrine carcinoma. 61
30246953 2018
27
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
28
Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. 61
29596894 2018
29
Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. 61
29742602 2018
30
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. 61
29491307 2018
31
Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. 61
31293777 2018
32
[Conversion Surgery after Etoposide/Cisplatin(EP)Therapy for Huge Pancreatic Neuroendocrine Carcinoma - A Case Report]. 61
29650928 2018
33
Laparoscopic Resection of a Pancreatic β Cell Tumor in a Dog. 61
28892425 2017
34
Differences between Grades G1 and G2 Hypovascular Pancreatic Neuroendocrine Tumors and Pancreatic Neuroendocrine Carcinoma. 61
28926309 2017
35
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. 61
28455360 2017
36
Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. 61
28487490 2017
37
Pancreatic neuroendocrine carcinoma with exocrine differentiation in a young cat. 61
28363254 2017
38
Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. 61
28521422 2017
39
Characterization of single lesion nonfunctioning pancreatic neuroendocrine carcinoma via computed tomography. 61
28454379 2017
40
The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. 61
28178157 2017
41
Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. 61
28331340 2017
42
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. 61
27838688 2017
43
[Surgical treatment and prognosis of pancreatic neuroendocrine carcinoma]. 61
27998470 2016
44
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. 61
27160433 2016
45
Clinical characteristics and management of insulin-producing neuroendocrine carcinomas. 61
27821028 2016
46
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. 61
26678407 2016
47
Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. 61
26984415 2016
48
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. 61
27142424 2016
49
A malignant cause of hypoglycaemia: a metastatic insulin-secreting pancreatic neuroendocrine carcinoma. 61
26994053 2016
50
A giant non-functioning pancreatic neuroendocrine carcinoma founded as an incidentaloma successfully treated with pancreatoduodenectomy. 61
27713785 2016

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 SSTR5 SSTR2 SST PTHLH PPY NCAM1
2 11.26 NCAM1 INS AFP
3 11.26 SSTR5 SSTR2 SST GCG

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 SST SERPINA3 PTHLH PPY INS GCG
2 endoplasmic reticulum lumen GO:0005788 9.46 MEN1 INS GCG AFP
3 secretory granule lumen GO:0034774 9.43 SERPINA3 INS GCG
4 extracellular region GO:0005576 9.32 SST SERPINA3 PTHLH PPY NCAM1 INS

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.55 SSTR5 SSTR2 SST PTHLH MEN1
2 glucose homeostasis GO:0042593 9.54 SSTR5 INS GCG
3 neuropeptide signaling pathway GO:0007218 9.5 SSTR5 SSTR2 PPY
4 osteoblast development GO:0002076 9.4 PTHLH MEN1
5 negative regulation of blood vessel diameter GO:0097756 9.26 INS CHGA
6 G protein-coupled receptor signaling pathway GO:0007186 9.23 SSTR5 SSTR2 SST PTHLH PPY INS
7 somatostatin signaling pathway GO:0038170 8.96 SSTR5 SSTR2

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 SST PTHLH PPY INS GCG GAST
2 somatostatin receptor activity GO:0004994 8.96 SSTR5 SSTR2

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....